Skip to content

Does Medicaid cover Ozempic, Wegovy or Zepbound?

By the glp1doses editorial team
Every number is checked against FDA labels and official price pages. How we check

The short answer

Whether Medicaid covers Ozempic, Wegovy or Zepbound depends on your state and on what the drug is prescribed for. Coverage of drugs used for weight loss is optional for state Medicaid programs, and CMS says Medicaid generally doesn't cover GLP-1s for weight loss. States can join the BALANCE Model through January 1, 2027. Check with your state plan.

Source: Federal Register

Key takeaways

  • Medicaid coverage of drugs used for weight loss is optional for each state, so there's no national answer.
  • A GLP-1 prescribed for another condition, such as diabetes, isn't being used for weight loss. Ask about that specific use.
  • Check your state Medicaid agency's preferred drug list or your managed care plan's formulary, or ask your pharmacist.
  • Ask whether your state joined BALANCE. CMS says the model doesn't guarantee coverage for any individual.
  • The Lilly and Novo Nordisk savings cards exclude people enrolled in Medicaid.

Medicaid is run state by state, and GLP-1 coverage for weight loss is one of the places where that shows most. There’s no single national answer to “does Medicaid cover Ozempic,” “does Medicaid cover Wegovy” or “does Medicaid cover Zepbound.” This page sets out what the federal sources say, and only that. It’s part of our Medicare and Medicaid guide to GLP-1s.

What federal law says

Federal Medicaid law lets states exclude certain drugs and uses from coverage. That list, in section 1927(d)(2) of the Social Security Act, includes agents when used for anorexia, weight loss or weight gain.

CMS, the federal agency behind Medicaid, describes the result this way: state Medicaid programs have discretion to cover the drugs on that list, including agents used for weight loss. Historically, the agency says, drugs used for weight loss have been an optional drug benefit for Medicaid programs.

Optional means exactly that. A state may cover GLP-1s for weight loss, cover them with conditions, or not cover them. CMS’s summary is that Medicare and Medicaid generally don’t cover these drugs for the weight loss indication.

The exclusion is about weight loss, not the drug

The optional category is defined by use. A GLP-1 prescribed for a condition other than weight loss isn’t being “used for weight loss.” For Medicare, CMS spells this out, naming type 2 diabetes and cardiovascular risk reduction as examples of other medically accepted indications. If your prescription is for diabetes, cardiovascular risk, sleep apnea or liver disease, ask your state plan about that specific use, because the answer may differ from its answer on weight loss.

The 2024 proposal that did not happen

In late 2024, CMS proposed to reinterpret the statute so that both Medicare Part D and Medicaid would cover anti-obesity medications for people with obesity. The proposal’s title covered its application to the Medicaid program as well.

It wasn’t finalized. The final rule published on April 15, 2025 listed “Part D Coverage of Anti-Obesity Medications (AOMs) and Application to the Medicaid Program” among the provisions CMS does not intend to finalize. State discretion remains the rule.

Where the BALANCE Model comes in

BALANCE is a voluntary CMS Innovation Center model. Under it, CMS negotiates GLP-1 drug pricing and coverage terms with manufacturers on behalf of state Medicaid agencies and Medicare Part D plan sponsors. The Medicaid side is the part that has started.

Here’s what the CMS documents say about Medicaid:

  • Timing. The model is tested from May 1, 2026 for participating states and runs through December 2031. State Medicaid agencies can join from May 2026 through January 1, 2027.
  • How a state joins. A state had to respond to the request for applications by July 31, 2026 and sign a State Agreement with CMS by January 1, 2027. The model is open to all states, the District of Columbia and US territories that take part in the Medicaid Drug Rebate Program.
  • Manufacturers. On March 9, 2026, CMS said it had completed negotiations with Eli Lilly and Novo Nordisk.
  • Drugs. All formulations of Mounjaro, Ozempic, Rybelsus and Wegovy, the KwikPen formulation of Zepbound, and Foundayo, for indications that are already covered and for weight management.
  • Coverage criteria. A participating state must apply prior authorization criteria no more burdensome than the negotiated criteria, without step therapy stricter than the drug’s FDA-approved label and without step therapy tied to lifestyle requirements, and for FDA-approved indications only. A state may choose less restrictive criteria, as long as they stay within the FDA-approved label.
  • Lifestyle support. Everyone receiving a GLP-1 for weight management under the model in Medicaid gets access to a lifestyle support program, provided by the manufacturer at no cost.

Now the limits. Participation is voluntary for manufacturers and for states. CMS says coverage in Medicaid will depend on participation by drug manufacturers and states, that patients would be subject to the negotiated qualifications including certain prior authorization requirements, and that the model will not guarantee coverage for any individual.

The BALANCE Model page covers the model as a whole, including why the Medicare side hasn’t launched.

If you have both Medicare and Medicaid

If you have both programs and your prescription drug coverage is a Medicare Part D plan, the Medicare rules are the ones to read. The Medicare GLP-1 Bridge is open to people in the LI NET program and in Special Needs Plans, among other plan types, and Extra Help doesn’t reduce its copay. The Bridge explainer has the criteria, and the eligibility checker applies them.

How to check your state

  1. Find out how your Medicaid drug benefit is run. Some people are in a managed care plan with its own drug list. Others are covered directly by the state. Your Medicaid card or enrollment letter names the plan.
  2. Look up the drug list. Search your state Medicaid agency’s site for its preferred drug list, or your managed care plan’s formulary (its list of covered drugs), and look for the medicine by brand name.
  3. Ask about the use, not only the drug. “Is Wegovy covered for weight management?” and “Is Wegovy covered for cardiovascular risk reduction?” can have different answers.
  4. Ask what prior authorization requires. Prior authorization is the plan’s approval before it pays. If the drug is covered with conditions, your prescriber’s office needs the criteria. The appeal letter generator can draft the supporting request.
  5. Ask whether your state has joined BALANCE, and if so, when coverage under it begins.

Your pharmacist can often run a test claim that shows right away whether the plan pays and what it requires.

If your state does not cover it

Manufacturer savings cards aren’t an option, because they exclude people enrolled in Medicaid. That leaves the manufacturers’ self-pay programs, which are cash programs with their own eligibility terms. Their prices start at $149 a month for the Wegovy pill, $149 for Foundayo and $299 for Zepbound, and go up with dose. Read the terms before you rely on a price, because some listings say government beneficiaries are excluded.

The without-insurance guide goes through each medicine’s cash price, and the cheapest path finder ranks the routes.

Frequently asked questions

Does Medicaid cover Ozempic?

It depends on your state and on what Ozempic is prescribed for. The category federal law makes optional for states is defined by use: drugs used for weight loss. A GLP-1 prescribed for another condition, such as diabetes, isn't being used for weight loss. Ozempic is also among the drugs CMS negotiated under the BALANCE Model. Ask your state plan about your specific use.

Does Medicaid cover Wegovy for weight loss?

Only if your state has chosen to. CMS says state Medicaid programs have discretion to cover drugs used for weight loss, which makes it an optional benefit, and that Medicaid generally doesn't cover GLP-1 drugs for the weight loss indication. For a reliable answer, ask your state Medicaid agency or check your managed care plan's drug list.

Does Medicaid cover Zepbound?

The same rule applies: coverage for weight loss is each state's decision. Under the BALANCE Model, the drugs CMS negotiated include the KwikPen formulation of Zepbound, for weight management as well as uses that are already covered. But that's only in states that join, and CMS says the model doesn't guarantee coverage for any individual.

Which states cover GLP-1s for weight loss under Medicaid?

State policies change. Your state Medicaid agency's preferred drug list, or your Medicaid managed care plan's formulary, is the authoritative source. Your pharmacist or prescriber's office can usually check it for you in a few minutes.

What does the BALANCE Model do for Medicaid?

It lets CMS negotiate GLP-1 pricing and coverage terms with manufacturers on behalf of state Medicaid agencies. Joining is voluntary for states. State Medicaid agencies can join from May 2026 through January 1, 2027, and people receiving a GLP-1 for weight management under the model get access to a manufacturer-provided lifestyle support program at no cost.

Can I use a manufacturer savings card if I have Medicaid?

No. The Lilly and Novo Nordisk savings cards exclude people enrolled in Medicaid and other government programs. If your state doesn't cover the drug, your remaining options are a prior authorization or appeal where the state has a pathway, or paying cash through a manufacturer's self-pay program where its terms allow.

Sources (16)

  1. 1.
    Federal Register: Medicare and Medicaid Programs; Contract Year 2026 Policy and Technical Changes to the Medicare Advantage Program, Medicare Prescription Drug Benefit Program, Medicare Cost Plan Program, and Programs of All-Inclusive Care for the Elderly (proposed rule, 89 FR 99340)
    “Currently, state Medicaid programs have discretion to cover the drugs or classes of drugs listed in section 1927(d)(2) of the Act, including “agents used for . . . weight loss . . .””
  2. 2.
    CMS: BALANCE (Better Approaches to Lifestyle and Nutrition for Comprehensive hEalth) Model
    “GLP-1 drugs for weight loss, along with lifestyle interventions, can help people improve their overall health, but GLP-1s are expensive and currently Medicare and Medicaid generally do not cover these drugs for the weight loss indication.”
  3. 3.
    Federal Register: Medicare and Medicaid Programs; Contract Year 2026 Policy and Technical Changes to the Medicare Advantage Program, Medicare Prescription Drug Benefit Program, Medicare Cost Plan Program, and Programs of All-Inclusive Care for the Elderly (proposed rule, 89 FR 99340)
    “The statutory definition of a covered Part D drug at section 1860D-2(e)(2) of the Social Security Act (the Act) excludes certain drugs and uses—specifically, those that may be excluded by Medicaid under section 1927(d)(2) of the Act. This includes, at section 1927(d)(2)(A) of the Act, “agents when used for anorexia, weight loss, or weight gain.” Historically, drugs used for weight loss have been excluded from the definition of covered Part D drug, regardless of their use for treatment of individuals with obesity, and have been an optional drug benefit for Medicaid programs.”
  4. 4.
    Federal Register: Medicare and Medicaid Programs; Contract Year 2026 Policy and Technical Changes to the Medicare Advantage Program, Medicare Prescription Drug Benefit Program, Medicare Cost Plan Program, and Programs of All-Inclusive Care for the Elderly (final rule, 90 FR 15792)
    “We also do not intend to finalize the following provisions from the proposed rule: Enhancing Health Equity Analyses: Annual Health Equity Analysis of Utilization Management Policies and Procedures, Part D Coverage of Anti-Obesity Medications (AOMs) and Application to the Medicaid Program, and Ensuring Equitable Access to Medicare Advantage Services—Guardrails for Artificial Intelligence (AI).”
  5. 5.
    CMS: BALANCE (Better Approaches to Lifestyle and Nutrition for Comprehensive hEalth) Model
    “The BALANCE Model, which stands for Better Approaches to Lifestyle and Nutrition for Comprehensive hEalth, aims to increase access to select glucagon‐like peptide‐1 (GLP-1) medications and healthy lifestyle interventions — to help people with Medicare and Medicaid improve their health. As part of this voluntary model, CMS will negotiate drug pricing and coverage terms with manufacturers of GLP-1 medications on behalf of state Medicaid agencies and Medicare Part D plan sponsors.”
  6. 6.
    CMS: BALANCE (Better Approaches to Lifestyle and Nutrition for Comprehensive hEalth) Model
    “Participation in BALANCE is voluntary for manufacturers, state Medicaid agencies, and Part D plans.”
  7. 7.
    CMS: Better Approaches to Lifestyle and Nutrition for Comprehensive hEalth (BALANCE) Model: Request for Applications, State Medicaid Agency
    “The CMS Innovation Center is testing this model beginning on May 1, 2026, for participating States and January 1, 2027, for participating Part D sponsors. The model will run through December 2031.”
  8. 8.
    CMS: Innovation Insight: Affordability of GLP-1s Takes Next Step with BALANCE Model RFAs
    “CMS has successfully completed negotiations with manufacturers Eli Lilly and Novo Nordisk, a significant milestone in carrying out the BALANCE model, and State Medicaid Agencies and Part D plan sponsors can now apply to participate in BALANCE, another critical step to making GLP-1s more affordable and available to people with Medicare Part D and Medicaid.”
  9. 9.
    CMS: BALANCE (Better Approaches to Lifestyle and Nutrition for Comprehensive hEalth) Model
    “All formulations of Mounjaro®, Ozempic®, Rybelsus®, and Wegovy®, the KwikPen formulation of Zepbound®, and Foundayo™. These are included for both currently covered indications (ex: type 2 diabetes) as well as weight management indications.”
  10. 10.
    CMS: BALANCE (Better Approaches to Lifestyle and Nutrition for Comprehensive hEalth) Model
    “State Medicaid agencies can join the model beginning in May 2026 through January 1, 2027. [...] Coverage in the Medicaid program will depend on participation by drug manufacturers and states. Patients would be subject to qualifications set by the negotiations between CMS and participating manufacturers, including certain prior authorization requirements. Therefore, this model will not guarantee coverage for any individual.”
  11. 11.
    CMS: Better Approaches to Lifestyle and Nutrition for Comprehensive hEalth (BALANCE) Model: Request for Applications, State Medicaid Agency
    “Model participation is open to all states, the District of Columbia, and all U.S. territories that participate in the Medicaid Drug Rebate Program (MDRP). [...] States will participate in the model by responding to this state RFA by no later than July 31, 2026, and executing a SA with CMS by January 1, 2027.”
  12. 12.
    CMS: Better Approaches to Lifestyle and Nutrition for Comprehensive hEalth (BALANCE) Model: Request for Applications, State Medicaid Agency
    “The prior authorization criteria applied must be: (i) no more burdensome than the criteria listed in Section 2.7.3; (ii) without step therapy that is more burdensome than the applicable model drug’s FDA-approved label (and no such step therapy or utilization may include step therapy related to lifestyle or similar requirements); and (iii) for FDA-approved indications only. [...] The participating state may choose to adopt Coverage Criteria that are less restrictive at their discretion, provided the criteria remain within the FDA approved label.”
  13. 13.
    CMS: BALANCE (Better Approaches to Lifestyle and Nutrition for Comprehensive hEalth) Model
    “All beneficiaries receiving GLP-1s for weight management under the BALANCE model in Medicaid will be provided with access to a lifestyle support program, provided by the manufacturer at no cost.”
  14. 14.
  15. 15.
  16. 16.